Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia

Chest

Volumn 114, Issue 2, 1998, Pages 411-415

  Cazzola, Mario ^a   Imperatore, Francesco ^a   Salzillo, Antonello ^a   Di Perna, Felice ^a   Calderaro, Francesco ^a   Imperatore, Aldo ^a   Matera, Maria Gabriella ^a  

^a NONE

Author keywords

Cardiac arrhythmias; Chronic obstructive pulmonary disease; Formoterol; Hypoxemia; Plasma potassium; Salmeterol

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL; SALMETEROL;

ADULT; ARTERIAL GAS; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; FEMALE; HEART ARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HOLTER MONITORING; HUMAN; HYPOXEMIA; INHALATIONAL DRUG ADMINISTRATION; MALE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SPIROMETRY;

EID: 0031810916     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.114.2.411     Document Type: Article

References (21)

1. Sarubbi B, Esposito V, Ducceschi V, et al. Effect of blood gas derangement on QTc dispersion in severe chronic obstructive pulmonary disease: evidence of an electropathy? Int J Cardiol 1997; 58:287-92
2. Conradson TB, Eklundh G, Olofsson B, et al. Cardiac arrhythmias in patients with mild-to-moderate obstructive pulmonary disease: comparison of beta-agonist therapy alone and in combination with a xanthine derivative, enprophylline or theophylline. Chest 1985; 88:537-42
3. Kemp JP, Bierman CW, Cocchetto DM. Dose-response study of inhaled salmeterol in asthmatic patients with 24-hour spirometry and Holter monitoring. Ann Allergy 1993; 70: 316-22
4. Nathan RA, Seltzer JM, Kemp JP, et al. Safety of salmeterol in the maintenance treatment of asthma. Ann Allergy Asthma Immunol 1995; 75:243-48
5. Maesen FP, Costongs R, Smeets JJ, et al. The effect of maximal doses of formoterol and salbutamol from a metered dose inhaler on pulse rates, ECG, and serum potassium concentration. Chest 1991; 99:1367-73
6. Seider N, Abinader EG, Oliven A. Cardiac arrhythmias after inhaled bronchodilators in patients with COPD and ischemic heart disease. Chest 1993; 104:1070-74
7. Cazzola M, Matera MG, Santangelo G, et al. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 1995; 89:357-62
8. American Thoracic Society. Standards for diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136:225-44
9. Gorecka D. Cardiac arrhythmias in chronic obstructive pulmonary disease. Monaldi Arch Chest Dis 1997; 52:278-81
10. Stewart AG, Waterhouse JC, Howard T. The QTc interval, autonomie neuropathy and mortality in hypoxaemic COPD. Respir Med 1995; 89:79-84
11. Bremner P, Burgess CD, Crane J, et al. Cardiovascular effects of fenoterol under conditions of hypoxaemia. Thorax 1992; 47:814-17
12. Jenne JW. Physiologic actions of beta-adrenergic agonists. In: Leff AR, ed. Pulmonary and critical care pharmacology and therapeutics. New York: McGraw-Hill, 1996; 473-87
13. Viegas CA, Ferrer A, Montserrat JM, et al. Ventilation-perfusion response after fenoterol in hypoxemic patients with stable COPD. Chest 1996; 110:71-77
14. Cazzola M, Santangelo G, Piccolo A, et al. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 1994; 7:103-07
15. Naline E, Zhang Y, Qian Y, et al. Relaxant effects and duration of action of formoterol and salmeterol on the isolated human bronchus. Eur Respir J 1994; 7:914-20
16. 2-adrenoceptors in both atria and ventricles in severe congestive cardiomyopathy. J Cardiovasc Pharmacol 1986; 8:1235-42
17. Vaughan Williams EM. Cardiac electrophysiologic effects of selective adrenoceptor stimulation and their possible roles in arrhythmias. J Cardiovasc Pharmacol 1985; 7(suppl 5):S61-64
18. Vick RL, Todd EP, Luedke DW. Epinephrine-induced hypokalaemia: relation to liver and skeletal muscle. J Pharmacol Exp Ther 1972; 181:139-46
19. Clapham JC, Hamilton TC. Effects of BRL38227, salbutamol, and aminophylline alone and in combination, on plasma potassium and on the heart. Drug Dev Res 1992; 26:157-72
20. Till MD. Cardiovascular and metabolic effects of eformoterol in adults. Br J Clin Pract 1995; 81(suppl):2-3
21. Bremner P, Woodman K, Burgess C, et al. A comparison of the cardiovascular and metabolic effects of formoterol, salbutamol and fenoterol. Eur Respir J 1993; 6:204-10